Synapse - Robert Motzer

Results (1248)

Sunitinib tolerance following an initial exposure period: Results of longitudinal PRO data from S-TRAC study

Meeting Abstract

George, D. J.; Figlin, R.; Motzer, R. J.; Paty, J.; Lechuga Frean, M. J.; Zanotti, G.; Bhattacharyya, H.; Ramaswamy, K.; Deannuntis, L.; Ravaud, A.
Annals of Oncology (2018)

Fulltext@MSK | Save

A phase III, randomized, placebo-controlled trial of adjuvant nivolumab plus ipilimumab in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after radical or partial nephrectomy (CheckMate 914)

Meeting Abstract

Bex, A.; Grünwald, V.; Russo, P.; Tomita, Y.; Berghorn, E.; McHenry, M. B.; Motzer, R. J.
Annals of Oncology (2018)

Fulltext@MSK | Save

Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis

Meeting Abstract

McDermott, D. F.; Rini, B. I.; Motzer, R. J.; Tannir, N. M.; Escudier, B.; Kollmannsberger, C. K.; Hammers, H. J.; Porta, C.; George, S.; Donskov, F.; more...
Annals of Oncology (2018)

Fulltext@MSK | Save

Safety and tolerability of atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC): Pooled analysis of IMmotion150 and IMmotion151

Meeting Abstract

Suarez, C.; Choueiri, T. K.; McDermott, D. F.; Escudier, B.; Atkins, M. B.; Powles, T. B.; Rini, B. I.; Motzer, R. J.; Pal, S. K.; Fong, L.; more...
Annals of Oncology (2018)

Fulltext@MSK | Save

Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (pts) with previously untreated advanced renal cell carcinoma (aRCC): CheckMate 214

Meeting Abstract

Rini, B. I.; Tannir, N. M.; Escudier, B.; McDermott, D. F.; Grimm, M. O.; Porta, C.; Powles, T.; Kollmannsberger, C. K.; Gurney, H. P.; Tykodi, S. S.; more...
Annals of Oncology (2018)

Fulltext@MSK | Save

Correlative analyses of serum biomarkers and efficacy outcomes in the randomized phase II trial of lenvatinib (LEN), everolimus (EVE), or LEN+EVE in patients with metastatic renal cell carcinoma

Meeting Abstract

Lee, C. H.; Motzer, R. J.; Glen, H.; Michaelson, M. D.; Larkin, J.; Minoshima, Y.; Kanekiyo, M.; Dairiki, R.; Sachdev, P.; Dutcus, C. E.; more...
Annals of Oncology (2018)

Fulltext@MSK | Save

PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials

Meeting Abstract

Choueiri, T. K.; Flaifel, A.; Xie, W.; Braun, D.; Ficial, M.; Jennings, R.; Nassar, A.; Escudier, B.; George, D. J.; Motzer, R. J.; more...
Annals of Oncology (2018)

Fulltext@MSK | Save

Comparative genomic profiling of matched primary and metastatic tumors in renal cell carcinoma

Journal Article

Becerra, M. F.; Reznik, E.; Redzematovic, A.; Tennenbaum, D. M.; Kashan, M.; Ghanaat, M.; Casuscelli, J.; Manley, B.; Jonsson, P.; DiNatale, R. G.; more...
European Urology Focus (2018)

Fulltext@MSK | Save

Genomically annotated risk model for advanced renal-cell carcinoma: A retrospective cohort study

Journal Article

Voss, M. H.; Reising, A.; Cheng, Y.; Patel, P.; Marker, M.; Kuo, F.; Chan, T. A.; Choueiri, T. K.; Hsieh, J. J.; Hakimi, A. A.; more...
Lancet Oncology (2018)

Fulltext@MSK | Save

IMmotion151: A randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC)

Meeting Abstract

Motzer, R. J.; Powles, T.; Atkins, M. B.; Escudier, B.; McDermott, D. F.; Suarez, C.; Bracarda, S.; Stadler, W. M.; Donskov, F.; Lee, J. L.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save